Evidence map›Paper›PMID 40175666›Full record

ArticleNature cell biology2025

Modulation of bone marrow haematopoietic stem cell activity as a therapeutic strategy after myocardial infarction: a preclinical study.

Jasmin Rettkowski, Mari Carmen Romero-Mulero, Indranil Singh, Carolin Wadle, Jan Wrobel, Diana Chiang, Natalie Hoppe, Julian Mess, Katharina Schönberger, Maria-Eleni Lalioti and 24 more

Abstract read
In one paragraph

Article in Nature cell biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Cytotoxic CD4Nature aging · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Macrophages and the Survival of Cardiomyocytes After Myocardial Infarction.Arteriosclerosis, thrombosis, and vascular biology · 2026
    Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

Jasmin Rettkowski *Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.ORCID http://orcid.org/0009-0006-1504-0816
Mari Carmen Romero-Mulero *Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.ORCID http://orcid.org/0000-0002-6705-7613
Indranil SinghInstitute for Research in Biomedicine, Barcelona Institute for Science and Technology, Barcelona, Spain.ORCID http://orcid.org/0000-0002-2143-986X
Carolin WadleDepartment of Cardiology and Angiology, University Heart Center, Medical Center, University of Freiburg, Freiburg, Germany.
Jan WrobelDepartment of Cardiology and Angiology, University Heart Center, Medical Center, University of Freiburg, Freiburg, Germany.
Diana ChiangSpemann Graduate School of Biology and Medicine, Freiburg, Germany.
Natalie HoppeDepartment of Cardiology and Angiology, University Heart Center, Medical Center, University of Freiburg, Freiburg, Germany.
Julian MessMax Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.
Katharina SchönbergerMax Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.
Maria-Eleni LaliotiMax Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.
Karin JäckleinMax Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.
Beatriz SilvaRegoMax Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.
Timon BühlerDepartment of Cardiology and Angiology, University Heart Center, Medical Center, University of Freiburg, Freiburg, Germany.
Noémie KarabaczMax Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.
Mirijam EggMax Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.
Helen DemollinMax Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.
Nadine ObierMax Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.
Yu Wei ZhangMax Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.
Claus JülicherDepartment of Cardiology and Angiology, University Heart Center, Medical Center, University of Freiburg, Freiburg, Germany.
Anne HetkampDepartment of Cardiology and Angiology, University Heart Center, Medical Center, University of Freiburg, Freiburg, Germany.
Martin CzernyFaculty of Medicine, University of Freiburg, Freiburg, Germany.
Michael-Jason JonesMax Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.
Hana SeungDepartment of Cardiology and Angiology, University Heart Center, Medical Center, University of Freiburg, Freiburg, Germany.
Ritika JainCardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Constantin von Zur MühlenDepartment of Cardiology and Angiology, University Heart Center, Medical Center, University of Freiburg, Freiburg, Germany.
Alexander MaierDepartment of Cardiology and Angiology, University Heart Center, Medical Center, University of Freiburg, Freiburg, Germany.ORCID http://orcid.org/0000-0003-0200-7495
Achim LotherInstitute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Ingo HilgendorfDepartment of Cardiology and Angiology, University Heart Center, Medical Center, University of Freiburg, Freiburg, Germany.
Peter van GalenDivision of Hematology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-0735-1570
Antonia KresoCardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-0632-958X
Dirk WestermannDepartment of Cardiology and Angiology, University Heart Center, Medical Center, University of Freiburg, Freiburg, Germany.
Alejo E Rodriguez-FraticelliInstitute for Research in Biomedicine, Barcelona Institute for Science and Technology, Barcelona, Spain.ORCID http://orcid.org/0000-0002-4017-8714
Timo HeidtDepartment of Cardiology and Angiology, University Heart Center, Medical Center, University of Freiburg, Freiburg, Germany. timo.heidt@uniklinik-freiburg.de.ORCID http://orcid.org/0000-0002-9607-7963
Nina Cabezas-WallscheidMax Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany. nina.cabezas@hest.ethz.ch.ORCID http://orcid.org/0000-0003-0870-0530

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myocardial infarction (MI) is a major global health concern. Although myeloid cells are crucial for tissue repair in emergency haematopoiesis after MI, excessive myelopoiesis can exacerbate scarring and impair cardiac function. Bone marrow (BM) haematopoietic stem cells (HSCs) have the unique capability to replenish the haematopoietic system, but their role in emergency haematopoiesis after MI has not yet been established. Here we collected human sternal BM samples from over 150 cardiac surgery patients, selecting 49 with preserved cardiac function. We show that MI causes detrimental transcriptional and functional changes in human BM HSCs. Lineage tracing experiments suggest that HSCs are contributors of pro-inflammatory myeloid cells infiltrating cardiac tissue after MI. Therapeutically, enforcing HSC quiescence with the vitamin A metabolite 4-oxo-retinoic acid dampens inflammatory myelopoiesis, thereby modulating tissue remodelling and preserving long-term cardiac function after MI.

Indexed as

Bone Marrow CellsHematopoietic Stem CellsHematopoietic Stem Cell TransplantationMyelopoiesisMyocardial InfarctionAgedAnimalsFemaleHumansMaleMiceMice, Inbred C57BLMiddle AgedMyeloid CellsTretinoinTretinoin

Identifiers

PMID40175666
PMCPMC11991920

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.